Petros Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit)
Petros Pharmaceuticals, Inc. (PTPI) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-04-15
- Petros Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2020-12-31 was -$1.24M.
- Petros Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2020-09-30 was -$2.46K.
- Petros Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2020-06-30 was -$164.39K.
- Petros Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2020-03-31 was -$29.97K.
- Petros Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- Petros Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- Petros Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- Petros Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2021 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-04-15 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-04-15 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-03-31 | |||
| 2020-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$1.24M derived: sum of 2 quarters · filed 2022-03-31 | -$1.40M derived: sum of 3 quarters · filed 2022-03-31 | -$1.43M 10-K · filed 2022-03-31 |
| 2020-09-30 | -$2.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$166.85K derived: sum of 2 quarters · filed 2021-11-15 | -$196.82K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$164.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$194.36K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$29.97K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |